The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of neoadjuvant chemoradiotherapy with 5-FU, cisplatin, mitomycin C, and heparin for borderline resectable pancreatic cancer.
Taizo Hibi
No relevant relationships to disclose
Minoru Kitago
No relevant relationships to disclose
Koichi Aiura
No relevant relationships to disclose
Minoru Tanabe
No relevant relationships to disclose
Osamu Itano
No relevant relationships to disclose
Masahiro Shinoda
No relevant relationships to disclose
Yuta Abe
No relevant relationships to disclose
Hiroshi Yagi
No relevant relationships to disclose
Yuko Kitagawa
No relevant relationships to disclose